跳至主要内容
临床试验/NCT04577651
NCT04577651已完成不适用

Study to Evaluate Boston Scientific Vercise Cartesia 16-contact Directional Lead (X/HX) With Deep Brain Stimulation (DBS) Systems for the Treatment of Parkinson's Disease (PD)

Boston Scientific Corporation14 个研究点 分布在 3 个国家目标入组 58 人开始时间: 2020年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58
试验地点
14
主要终点
Change in Motor Function

研究概览

简要总结

The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the treatment of Parkinson's Disease (PD).

详细描述

Subjects will receive Deep Brain Stimulation with a 16-contact Directional Lead to treat their Parkinson's Disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Candidate for DBS implant in the treatment of Parkinson's disease
  • Must be on stable anti-parkinsonian medications for 28 days prior to Informed Consent
  • Persistent disabling Parkinson's disease symptoms such as dyskinesias, motor fluctuations, or disabling "off" periods despite optimal medical therapy
  • Be willing and able to comply with all visits and study related procedures (e.g., using the remote control, charging system, etc.).

排除标准

  • Any intracranial abnormality or medical condition that would contraindicate DBS surgery
  • Have any significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol (e.g. bipolar, schizophrenia, mood disorder with psychotic features, cluster B personality disorders)
  • Any current drug or alcohol abuse, as determined by the investigator
  • Any history of recurrent or unprovoked seizures

结局指标

主要结局

Change in Motor Function

时间窗: 12 weeks post device-activation

Mean change in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating (MDS-UPDRS) Part III scores from Baseline in meds off condition to 12 weeks post device-activation in stim on/meds off condition. Range 0 - 108. Higher scores indicate worse function.

次要结局

  • Change in Motor Function(52 weeks post device-activation)
  • Change in Quality of Life(52 weeks post device-activation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验